Utilizing brain MRI and cognitive assessments, the newly FDA-approved, AI-powered software platform BrainSee can reportedly predict the progression of amnestic mild cognitive impairment (aMCI) to Alzheimer’s dementia within five years.
The Food and Drug Administration (FDA) has granted De Novo approval for BrainSee, a software platform that may predict up to a five-year progression of amnestic mild cognitive impairment (aMCI) to Alzheimer’s dementia, based on a combined artificial intelligence (AI) assessment of brain MRI and cognitive assessments.
Through the aforementioned combination, BrainSee generates an automated score that notes the likelihood of progression from aMCI to Alzheimer’s dementia, according to Darmiyan, Inc., the developer of the software platform.
Darmiyan emphasized that for patients with aMCI deemed to be at high risk for developing Alzheimer’s dementia within five years, the predictive screening capability afforded by BrainSee may facilitate personalized treatment. For those deemed to be at lower risk of Alzheimer’s dementia progression, the non-invasive BrainSee risk stratification may decrease patient anxiety as well as costs of more invasive tests, according to Darmiyan.
"Our vision is to redefine brain health screening and monitoring standards and impact the lives of patients and their family members in a meaningful way,” noted Padideh Kamali-Zare, Ph.D., the founder and CEO of Darmiyan. “BrainSee is the first product of this vision, backed by our solid technological infrastructure that is capable of driving further transformations and scalable innovations in the brain health landscape.”
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.